Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Snake envenomation in Florida: a 20-year analysis of epidemiology and clinical outcomes at a tertiary medical centre.
Trans R Soc Trop Med Hyg
January 2025
University of Florida College of Medicine, Gainesville, 32610 USA.
Background: Venomous snakes are among the most lethal animals worldwide and envenomation survivors face lifelong morbidities. Envenomation is colloquially considered highly prevalent in the US state of Florida, yet envenomation trends here are currently unassessed.
Methods: We present a comprehensive analysis of causes, characteristics and treatments of Florida's snake envenomations via medical records review of envenomated patients presenting to a major academic medical centre between 2002 and 2022.
Medical management of a child treated for two unique envenomation episodes via captive snakes in a 60-day period: A case report.
Heliyon
November 2024
Department of Poisoning and Occupational Diseases, Emergency Medicine, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Venomous snake bites can result in irreversible damage, leading to respiratory dysfunction, bleeding disorders, kidney damage, or serious complications. In recent years, with the popularity of online shopping in China, snakes can be easily purchased and kept as pets, even if some areas are not natural habitats for certain kinds of snakes. A 13-year-old boy purchased two venomous snakes online as pets.
View Article and Find Full Text PDFAfter the bite: evaluating a specialized clinic for follow-up care for snake envenomation.
Clin Toxicol (Phila)
November 2024
Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Article Synopsis
- The observational study involved 52 patients, primarily male with a median age of 29, highlighting common envenomations, persistent symptoms, and treatments provided, including compression and physical therapy.
- Key findings indicated that 61.5% of patients had persistent edema, with the clinic effectively addressing significant post-discharge issues through comprehensive wound care and referrals.
Oral varespladib for the treatment of snakebite envenoming in India and the USA (BRAVO): a phase II randomised clinical trial.
BMJ Glob Health
October 2024
Ophirex, Inc, Corte Madera, California, USA.
Article Synopsis
- Snakebite envenoming (SBE) causes over 500,000 deaths or serious injuries annually, and a phase II clinical trial was conducted to evaluate the safety and efficacy of varespladib methyl, an oral treatment, in patients bitten by venomous snakes.
- The trial, which was double-blind and placebo-controlled, enrolled patients in emergency departments in the USA and India, assessing changes in severity of snakebite symptoms using the Snakebite Severity Score (SSS) after treatment.
- Results indicated no significant difference in SSS improvement between the varespladib and placebo groups overall, but early treatment (within 5 hours of the bite) showed potential benefits in illness severity and recovery outcomes.
Article Synopsis
- This study compared the effectiveness and safety of two FDA-approved antivenoms, FabAV (Crotalidae polyvalent immune fab) and Fab2AV (Crotalidae immune F(ab')) for treating eastern copperhead bites.
- Of the 134 patients analyzed, 89 received antivenom, with FabAV achieving 100% initial control compared to 89.8% for Fab2AV, while FabAV required fewer doses (median of 6 vials) than Fab2AV (median of 10 vials).
- Additionally, patients treated with Fab2AV experienced acute adverse reactions at a higher rate (11.9%) compared to none for FabAV.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!